img

Zosano Pharma Corporation (ZSAN) announces that its lead product candidate, M207, achieved both co-primary endpoints

13 Feb 2017, Monday

FREMONT, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) announces that its lead product candidate, M207, achieved both co-primary endpoints of pain freedom and most bothersome symptom freedom at 2 hours in the recently completed ZOTRIP trial. The ZOTRIP pivotal efficacy study was a multicenter, double-blind, randomized, placebo-controlled, dose-ranging trial comparing three doses (1.0mg, 1.9mg and 3.8mg) of M207, a novel transdermal therapeutic, to placebo for a…

Continue Reading